Navigation Links
Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
Date:8/12/2008

rms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included on Form 10-QSB for the quarter ending June 30, 2008.

Please see our Website: http://www.Lixte.com

For Investor Information, please contact:

Frank Benedetto

Mirador Consulting, Inc. 561-989-3600


'/>"/>
SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
2. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
3. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
4. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
5. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
9. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... Financial Highlights f or the ... : Revenues increased 58.1% to $24.2 million ... Net income rose 73.6% to $13.4 million, representing a net margin of 55.5% ... " ) increased to $0.80; Diluted EPS increased to $0.79 ...
... EMERYVILLE, Calif., March 28, 2011 Bionovo, Inc. (Nasdaq: ... and development of safe and effective treatments for women,s health ... Phase 1 clinical trial testing the safety of two doses ... hot flushes (study # MF101-008), also known as "menopausal hot ...
Cached Medicine Technology:Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 2Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 3Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 4Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 5Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 6Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 7Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 8Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011 9Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes 2Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes 3
(Date:7/9/2014)... innovative tool that captures heretofore hidden ways that cells ... protein that makes breast cancer cells more likely to ... cancer,s spread in part by blocking two other proteins ... suggests these two disease processes could have unexpected ties. ... 10 issue of Nature , points to the ...
(Date:7/9/2014)... scientific research into the metabolism of stromal support cells ... metabolism of these cell types in the development of ... inflammatory conditions and cancer. That was the conclusion of ... Leuven in the leading journal Nature . , ... of wake-up call. The metabolism of cancer cells has ...
(Date:7/9/2014)... R.I. Researchers have found that fecal transplantation ... in immunocompromised patients. This is the result of ... in the Center for Women,s Gastrointestinal Medicine at The ... been published online in advance of print in the ... difficile , or C. diff , has increased ...
(Date:7/9/2014)... R.I. -- Researchers from The Miriam Hospital ... disease (COPD) who are also depressed have difficulty ... to be particularly true for women, and screening ... as part of treatment. The study and its ... Medicine . , Chronic obstructive pulmonary disease ...
(Date:7/9/2014)... available in French . ... year old teens, including brain structure and function, personality, life ... will go on to develop binge drinking within the next ... other variables such as life events and a family history ... Whether or not the child had had a single ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Wake-up call for more research into cell metabolism 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:What drives a child to abuse alcohol? 2
... the big gameMINNEAPOLIS, Jan. 29 The Super Bowl ... it is for the actual football game. Among this ... Minnesota that somberly reminds Minnesotans that "we all pay ... consequences of tobacco use are explored though a series ...
... bugs" because our antibiotic arsenal has run dry, leaving the ... disease researchers at The University of Texas Medical School at ... New England Journal of Medicine , Barbara E. Murray, M.D., ... future response to preventing and treating "super bugs." , A ...
... National Family Planning and Reproductive Health AssociationWASHINGTON, Jan. 28 ... planning services makes sense. According to the Congressional ... SAVE the federal government more than $200 million over ... the rumors and inaccuracies that have flooded America,s airwaves ...
... Cream Moves from Athletic Roots to Help Arthritis PainPLEASANT ... season, a toxin-free pain relief cream was ... Brady, Willie McGinest and LaDainian Tomlinson. The pain ... and muscles. The idea was to help players ...
... kind finds no health downside to donation , , WEDNESDAY, Jan. ... life by donating a kidney tend to lead long, healthy ... follow-up of donors ever conducted. , "Their lifespan is comparable ... said study author Dr. Hassan N. Ibrahim, an associate professor ...
... January 28, 2009 A new study has found ... spinal cord, called ependymal stem cells, reverses paralysis associated with ... the population of these cells after spinal cord injury was ... The results open a new window on spinal cord regenerative ...
Cached Medicine News:Health News:New Super Bowl Ad Reminds Minnesotans: 'We All Pay the Price for Tobacco' 2Health News:New Super Bowl Ad Reminds Minnesotans: 'We All Pay the Price for Tobacco' 3Health News:Call to action: Running out of options to fight ever-changing 'super bugs' 2Health News:Call to action: Running out of options to fight ever-changing 'super bugs' 3Health News:Get the Facts the House Republicans Don't Want You to Have 2Health News:Pro Football Healthcare Generates Arthritis Pain Relief Cream 2Health News:Most Kidney Donors Lead Long, Healthy Lives 2Health News:Most Kidney Donors Lead Long, Healthy Lives 3Health News:Stem cells used to reverse paralysis in animals 2
A rapid, convenient, qualitative method for detecting asymptomatic occult bleeding....
... die each year of colon cancer ... improvements (high contrast berium enema, colonoscopy, ... in the success rate of curative ... been achieved over the past two ...
... use of guaiac as a test for the ... of phenolic compounds present in guaiac to quinones, ... If blood is present, the heme portion of ... manner, catalyzing the release of oxygen from hydrogen ...
... SENSA elitewas designed to improve patient compliance. ... and sample collection options make this fecal ... understand and complete. Diet guidelines are explained ... determine which foods and drugs are okay ...
Medicine Products: